# Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

> **NCT00494780** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 59 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisolone, Prednisone or equivalent

## Key facts

- **NCT ID:** NCT00494780
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-04
- **Final completion:** 2010-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494780, "Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00494780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*